Rigel Pharmaceuticals RIGL fostamatinib — Government contracts revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GovernmentAssistanceOperatingIncome.
The source filing: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026.
- Filed
- Mar 3, 2026, 4:06 PM EST
- Fiscal year
- FY2025
- Accession
- 0001034842-26-000015
Government contracts revenue of $0.3 million for the year ended December 31, 2025 was related to an award granted to us by BARDA for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress. No government contracts revenue was recognized during the year ended December 31, 2024. Government contracts revenue of $1.1 million for the year ended December 31, 2023 was primarily related to an award granted to us by the Department of Defense to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Rigel Pharmaceuticals's fostamatinib — government contracts revenue?
- Rigel Pharmaceuticals (RIGL) reported fostamatinib — government contracts revenue of $75K in Q4 2025.
- What is the long-term trend for Rigel Pharmaceuticals's fostamatinib — government contracts revenue?
- Over 2 years (2023 to 2025), Rigel Pharmaceuticals's fostamatinib — government contracts revenue has grown at a -47.8% compound annual growth rate (CAGR), from $1.1M to $300K.
- What does fostamatinib — government contracts revenue mean?
- Revenue derived specifically from government-funded research grants, development contracts, or procurement programs related to fostamatinib. This metric captures the extent to which public sector funding supports the development or distribution of the product. It serves as an indicator of non-dilutive financing and external validation of the drug's clinical utility.
Ask your AI about Rigel Pharmaceuticals's fostamatinib — government contracts revenue.
Connect your AI assistant and compare it to peers, right in your chat.
